Published in Ann N Y Acad Sci on October 01, 2004
Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. J Neurodev Disord (2012) 1.73
Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct (2005) 1.47
Poor response inhibition: at the nexus between substance abuse and attention deficit/hyperactivity disorder. Neurosci Biobehav Rev (2008) 1.30
Lack of cocaine self-administration in mice expressing a cocaine-insensitive dopamine transporter. J Pharmacol Exp Ther (2009) 1.27
Dopamine transporter mutant mice in experimental neuropharmacology. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.97
Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophr Bull (2009) 0.93
Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice. Psychopharmacology (Berl) (2013) 0.93
Impaired spatial working memory and decreased frontal cortex BDNF protein level in dopamine transporter knockout mice. Eur J Pharmacol (2009) 0.91
GSK-3β activity and hyperdopamine-dependent behaviors. Neurosci Biobehav Rev (2010) 0.88
Monoamine transporters: vulnerable and vital doorkeepers. Prog Mol Biol Transl Sci (2011) 0.87
False positive in the intravenous drug self-administration test in C57BL/6J mice. Behav Pharmacol (2011) 0.87
Intra-accumbens injection of a dopamine aptamer abates MK-801-induced cognitive dysfunction in a model of schizophrenia. PLoS One (2011) 0.77
Dopamine-mediated MK-801-induced elevation in food-based extinction responding in rats and associated changes in region-specific phosphorylated ERK. Psychopharmacology (Berl) (2010) 0.76
The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania. Neuropharmacology (2016) 0.76
Functional coding variation in the presynaptic dopamine transporter associated with neuropsychiatric disorders drives enhanced motivation and context-dependent impulsivity in mice. Behav Brain Res (2017) 0.75
MassBank: a public repository for sharing mass spectral data for life sciences. J Mass Spectrom (2010) 6.16
Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N Engl J Med (2008) 2.91
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res (2006) 2.62
Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. Brain Res (2005) 2.34
Pooled association genome scanning for alcohol dependence using 104,268 SNPs: validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. Am J Med Genet B Neuropsychiatr Genet (2006) 2.09
Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci (2006) 2.07
Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. Proc Natl Acad Sci U S A (2005) 2.00
Addiction molecular genetics: 639,401 SNP whole genome association identifies many "cell adhesion" genes. Am J Med Genet B Neuropsychiatr Genet (2006) 1.95
Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Mol Med (2010) 1.83
Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J Natl Cancer Inst (2012) 1.83
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet (2002) 1.73
Genome-wide association for methamphetamine dependence: convergent results from 2 samples. Arch Gen Psychiatry (2008) 1.72
Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease. Am J Med Genet B Neuropsychiatr Genet (2005) 1.60
Neurexin 3 polymorphisms are associated with alcohol dependence and altered expression of specific isoforms. Hum Mol Genet (2007) 1.56
Linkage disequilibrium, haplotype and association studies of a chromosome 4 GABA receptor gene cluster: candidate gene variants for addictions. Am J Med Genet B Neuropsychiatr Genet (2006) 1.51
Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout mice. Neuropsychopharmacology (2003) 1.48
The involvement of glucocorticoids in psychological stress-induced exacerbations of experimental allergic asthma. Int Arch Allergy Immunol (2014) 1.43
Human dopamine transporter gene variation: effects of protein coding variants V55A and V382A on expression and uptake activities. Pharmacogenomics J (2003) 1.42
Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology (2004) 1.41
Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. J Neurosci (2009) 1.33
A human-specific de novo protein-coding gene associated with human brain functions. PLoS Comput Biol (2010) 1.31
CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res (2011) 1.31
Genome-wide association for nicotine dependence and smoking cessation success in NIH research volunteers. Mol Med (2008) 1.27
A rotarod test for evaluation of motor skill learning. J Neurosci Methods (2010) 1.26
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One (2008) 1.26
NrCAM in addiction vulnerability: positional cloning, drug-regulation, haplotype-specific expression, and altered drug reward in knockout mice. Neuropsychopharmacology (2006) 1.24
Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol (2008) 1.23
How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci (2005) 1.22
Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem (2008) 1.19
Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics (2008) 1.19
G protein-activated inwardly rectifying potassium channels as potential therapeutic targets. Curr Pharm Des (2006) 1.19
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry (2007) 1.17
Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Nat Commun (2012) 1.16
Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice. J Biol Chem (2010) 1.16
Association between polymorphisms in the promoter region of the sialyltransferase 8B (SIAT8B) gene and schizophrenia. Biol Psychiatry (2005) 1.15
Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology (2004) 1.15
Genome wide association for substance dependence: convergent results from epidemiologic and research volunteer samples. BMC Med Genet (2008) 1.12
Dopamine D1 receptor-induced signaling through TrkB receptors in striatal neurons. J Biol Chem (2008) 1.12
Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci (2008) 1.12
A congenital muscular dystrophy with mitochondrial structural abnormalities caused by defective de novo phosphatidylcholine biosynthesis. Am J Hum Genet (2011) 1.11
Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain (2009) 1.11
Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology (2006) 1.09
SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum Mol Genet (2005) 1.08
Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators. J Exp Med (2013) 1.08
Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis. Nat Immunol (2013) 1.06
Association study of polymorphisms in the 5' upstream region of human DISC1 gene with schizophrenia. Neurosci Lett (2004) 1.06
Group III secreted phospholipase A2 regulates epididymal sperm maturation and fertility in mice. J Clin Invest (2010) 1.06
Molecular mechanisms of analgesia induced by opioids and ethanol: is the GIRK channel one of the keys? Neurosci Res (2002) 1.06
Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J Pain (2013) 1.06
Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol (2006) 1.05
Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs. Ann N Y Acad Sci (2010) 1.04
Genome wide association for addiction: replicated results and comparisons of two analytic approaches. PLoS One (2010) 1.04
Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes. Mol Med (2009) 1.02
Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs. Neuropsychopharmacology (2004) 1.01
Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology (2006) 1.01
Pharmacogenomics of the human µ-opioid receptor. Pharmacogenomics (2011) 1.01
OKCAM: an ontology-based, human-centered knowledgebase for cell adhesion molecules. Nucleic Acids Res (2008) 1.01
Molecular mechanisms underlying the rewarding effects of cocaine. Ann N Y Acad Sci (2004) 1.00
Genomic regions identified by overlapping clusters of nominally-positive SNPs from genome-wide studies of alcohol and illegal substance dependence. PLoS One (2011) 1.00
Association between KCNJ6 (GIRK2) gene polymorphisms and postoperative analgesic requirements after major abdominal surgery. PLoS One (2009) 1.00
mu-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion. Brain Res Mol Brain Res (2004) 1.00
Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem (2003) 1.00
Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol (2007) 1.00
Convergent genome wide association results for bipolar disorder and substance dependence. Am J Med Genet B Neuropsychiatr Genet (2009) 0.99
Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry (2010) 0.99
Active behaviours produced by antidepressants and opioids in the mouse tail suspension test. Int J Neuropsychopharmacol (2012) 0.99
Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Mol Pharmacol (2002) 0.98
Methylone and monoamine transporters: correlation with toxicity. Curr Neuropharmacol (2011) 0.98
Inhibition of G protein-activated inwardly rectifying K+ channels by fluoxetine (Prozac). Br J Pharmacol (2003) 0.98
Inducible cAMP early repressor acts as a negative regulator for kindling epileptogenesis and long-term fear memory. J Neurosci (2008) 0.98
Association of mu-opioid receptor gene polymorphism A118G with alcohol dependence in a Japanese population. Neuropsychobiology (2006) 0.97
Functional lacrimal gland regeneration by transplantation of a bioengineered organ germ. Nat Commun (2013) 0.97
Methods to study the behavioral effects and expression of CB2 cannabinoid receptor and its gene transcripts in the chronic mild stress model of depression. Methods Mol Med (2006) 0.97
Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis (2013) 0.97
KEPI, a PKC-dependent protein phosphatase 1 inhibitor regulated by morphine. J Biol Chem (2002) 0.96
Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis. PLoS Pathog (2012) 0.96
Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol (2002) 0.95
Global metabolomic analysis of heart tissue in a hamster model for dilated cardiomyopathy. J Mol Cell Cardiol (2013) 0.95
Reliability and validity of the Japanese version of the Addiction Severity Index (ASI-J). Nihon Arukoru Yakubutsu Igakkai Zasshi (2006) 0.95
The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands. Biochem Pharmacol (2005) 0.94
Supplementing high-density SNP microarrays for additional coverage of disease-related genes: addiction as a paradigm. PLoS One (2009) 0.94
Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans. Neurosci Lett (2003) 0.94